Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry

References

• American Psychiatric Association. Trauma and stressor-related disorders. Diagnostic and statistical manual of mental disorders (5th ed.). 2013.
   Google Scholar
• Yehuda R, Hoge CW, McFarlane AC, et al. Post-traumatic stress disorder. Nat Rev Dis Primers. 2015;1(1):15057.
   PubMedGoogle Scholar
• Sareen J. Posttraumatic stress disorder in adults: impact, comorbidity, risk factors, and treatment. Can J Psychiatry. 2014;59(9):460–467[cited Aug 1 2022]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168808/
   PubMed Web of Science ®Google Scholar
• Edmondson D, Kronish IM, Shaffer JA, et al. Posttraumatic stress disorder and risk for coronary heart disease: a meta-analytic review. Am Heart J. 2013;166(5):806–814.
   PubMed Web of Science ®Google Scholar
• Song H, Fang F, Tomasson G, et al. Association of stress-related disorders with subsequent autoimmune disease. JAMA. 2018;319(23):2388–2400.
   PubMed Web of Science ®Google Scholar
• McGowan I. The economic burden of PTSD. A brief review of salient literature. Int J Psychiatry Ment Health. 2019; 20–26. DOI:10.36811/ijpmh.2019.110003.
   Google Scholar
• Merz J, Schwarzer G, Gerger H. Comparative efficacy and acceptability of pharmacological, psychotherapeutic, and combination treatments in adults with posttraumatic stress disorder: a network meta-analysis. JAMA psychiatry. 2019;76(9):904–913.
   PubMed Web of Science ®Google Scholar
• Bisson JI, Roberts NP, Andrew M, et al. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst Rev. 2013;12:CD003388.
   Google Scholar
• Etten MLV, Taylor S. Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysis. Clin Psychol Psychother. 1998;5(3):126–144.
   Web of Science ®Google Scholar
• De Berardis D, Marini S, Serroni N, et al. Targeting the noradrenergic system in posttraumatic stress disorder: a systematic review and meta-analysis of prazosin trials. Curr Drug Targets. 2015;16(10):1094–106.
   PubMed Web of Science ®Google Scholar
• Berardis D, Fornaro M, Ventriglio A, et al. Trazodone add-on in COVID-19-related selective serotonin reuptake inhibitor-resistant post-traumatic stress disorder in healthcare workers: two case reports. Clin Psychopharmacol Neurosci. 2021;19(4):780–785.
   PubMed Web of Science ®Google Scholar
• De Berardis D, Conti CM, Marini S, et al. Is there a role for agomelatine in the treatment of anxiety disorders? A review of published data. Int J Immunopathol Pharmacol. 2013;26(2):299–304. 3.
   PubMed Web of Science ®Google Scholar
• Andre CM, Hausman J, Guerriero G. Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci. 2016;7:19. DOI:10.3389/fpls.2016.00019
   PubMed Web of Science ®Google Scholar
• Laprairie RB, Bagher AM, Kelly ME, et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790–4805.
   PubMed Web of Science ®Google Scholar
• Elmes MW, Kaczocha M, Berger WT, et al. Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD). J Biol Chem. 2015;290(14):8711–8721.
   PubMed Web of Science ®Google Scholar
• Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3):833.
   PubMed Web of Science ®Google Scholar
• Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001;56(11):1059–1068.
   PubMed Web of Science ®Google Scholar
• Hill MN, Campolongo P, Yehuda R, et al. Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder. Neuropsychopharmacol. 2018;43(1):80–102.
   PubMed Web of Science ®Google Scholar
• Campos AC, Moreira FA, Gomes FV, et al. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc B. 2012;367(1607):3364–3378.
   PubMed Web of Science ®Google Scholar
• Rock EM, Bolognini D, Limebeer CL, et al. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol. 2012;165(8):2620–2634.
   PubMed Web of Science ®Google Scholar
• Silvestro S, Schepici G, Bramanti P, et al. Molecular targets of cannabidiol in experimental models of neurological disease. Molecules. 2020;25(21):10.3390/molecules25215186.
   PubMed Web of Science ®Google Scholar
• Papagianni EP, Stevenson CW. Cannabinoid regulation of fear and anxiety: an update. Curr Psychiatry Rep. 2019;21(6):38.
   PubMed Web of Science ®Google Scholar
• Melas PA, Scherma M, Fratta W, et al. Cannabidiol as a potential treatment for anxiety and mood disorders: molecular targets and epigenetic insights from preclinical research. Int J Mol Sci. 2021;22(4):1863.
   PubMed Web of Science ®Google Scholar
• Ressler KJ, Berretta S, Bolshakov VY, et al. Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits. Nat Rev Neurol. 2022;1–16. doi: 10.1038/s41582-022-00635-8.
   Web of Science ®Google Scholar
• Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64(1):21–47.
   PubMed Web of Science ®Google Scholar
• Rabinak CA, Angstadt M, Lyons M, et al. Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans. Neurobiol Learn Mem. 2014;113:125–134
   PubMed Web of Science ®Google Scholar
• Dincheva I, Drysdale AT, Hartley CA, et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun. 2015;6(1):6395.
   PubMedGoogle Scholar
• Rabinak CA, Angstadt M, Sripada CS, et al. Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology. 2013;64(1):396–402.
   PubMedGoogle Scholar
• Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014;34(5):559–564.
   PubMed Web of Science ®Google Scholar
• Elms L, Shannon S, Hughes S, et al. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. J Altern Complement Med. 2019;25(4):392–397.
   PubMed Web of Science ®Google Scholar
• Roitman P, Mechoulam R, Cooper-Kazaz R, et al. Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig. 2014;34(8):587–591.
   PubMed Web of Science ®Google Scholar
• Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with PTSD. J Clin Psychiatry. 2015;76(9):1174–80.
   PubMed Web of Science ®Google Scholar
• Hirvonen J, Goodwin RS, Li C, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry. 2012;17(6):642–649.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–1499.
   PubMed Web of Science ®Google Scholar
• Erridge S, Salazar O, Kawka M, et al. An initial analysis of the UK Medical Cannabis Registry: outcomes analysis of first 129 patients. Neuropsychopharmacol Rep. 2021;41(3):362–370.
   PubMed Web of Science ®Google Scholar
• Roffman CE, Buchanan J, Allison GT. Charlson comorbidities index. J Physiother. 2016;62(3):171.
   PubMed Web of Science ®Google Scholar
• Creamer M, Bell R, Failla S. Psychometric properties of the impact of event scale—Revised. Behav Res Ther. 2003;41(12):1489–1496.
   PubMed Web of Science ®Google Scholar
• Bowen-Salter H, Kernot J, Baker A, et al. Self-reported outcome measures for adults with post-traumatic stress disorder: towards recommendations for clinical practice. Aust J Psychol. 2021;73(3):282–292.
   Web of Science ®Google Scholar
• Kawamura N, Kim Y, Asukai N. Suppression of cellular immunity in men with a past history of posttraumatic stress disorder. Am J Psychiatry. 2001;158(3):484–486.
   PubMed Web of Science ®Google Scholar
• Steel JL, Dunlavy AC, Stillman J, et al. Measuring depression and PTSD after trauma: common scales and checklists. Injury. 2011;42(3):288–300.
   PubMed Web of Science ®Google Scholar
• Position statement on use of the EQ-5D-5L value set for England (updated October 2019) | Technology appraisal guidance | NICE guidance | Our programmes | What we do | About. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l [cited 2022 Apr 28].
   Google Scholar
• van Hout B, Janssen MF, Feng Y, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–715.
   PubMed Web of Science ®Google Scholar
• Dams J, Rimane E, Steil R, et al. Reliability, validity and responsiveness of the EQ-5D-5L in assessing and valuing health status in adolescents and young adults with posttraumatic stress disorder: a randomized controlled trail. Psychiatr Q. 2021;92(2):459–471.
   PubMed Web of Science ®Google Scholar
• Snyder E, Cai B, DeMuro C, et al. A new single-item sleep quality scale: results of psychometric evaluation in patients with chronic primary insomnia and depression. J Clin Sleep Med. 2018;14(11):1849–1857.
   PubMed Web of Science ®Google Scholar
• Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Internal Med. 2006;166(10):1092–1097.
   PubMed Web of Science ®Google Scholar
• Johnson SU, Ulvenes PG, Øktedalen T, et al. Psychometric properties of the General Anxiety Disorder 7-item (GAD-7) scale in a heterogeneous psychiatric sample. Front Psychol. 2019;10:1473. DOI:10.3389/fpsyg.2019.01713.
   PubMed Web of Science ®Google Scholar
• Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004;27(1):26–35.
   PubMed Web of Science ®Google Scholar
• Swanenburg J, Gruber C, Brunner F, et al. Patients’ and therapists’ perception of change following physiotherapy in an orthopedic hospital’s outpatient clinic. Physiother Theory Pract. 2015;31(4):293–298.
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–181.
   PubMed Web of Science ®Google Scholar
• Coolican H. Research methods and statistics in psychology. 7th ed. London: Routledge; 2018.
   Google Scholar
• Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico medical cannabis program. J Psychoactive Drugs. 2014;46(1):73–77.
   PubMed Web of Science ®Google Scholar
• Cahill SP, Lunn SE, Diaz P, et al. Evaluation of patient reported safety and efficacy of cannabis from a survey of medical cannabis patients in Canada. Front Public Health. 2021;9. DOI:10.3389/fpubh.2021.626853.
   Web of Science ®Google Scholar
• LaFrance EM, Glodosky NC, Bonn-Miller M, et al. Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder. J Affect Disord. 2020;274 298–304. DOI:10.1016/j.jad.2020.05.132.
   Google Scholar
• Bonn-Miller MO, Sisley S, Riggs P, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial. PloS One. 2021;16(3):e0246990.
   PubMed Web of Science ®Google Scholar
• Loflin MJE, Babson K, Sottile J, et al. A cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis. Am J Drug Alcohol Abuse. 2019;45(5):506–513.
   PubMed Web of Science ®Google Scholar
• Rabinak CA, Blanchette A, Zabik NL, et al. Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults: a preliminary study. Psychopharmacology (Berl). 2020;237(6):1813–1826.
   PubMed Web of Science ®Google Scholar
• Bolsoni LM, Crippa JAS, Hallak JEC, et al. The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event. Rev Bras psiquiatr (Sao Paulo, Brazil: 1999). 2022;44(3):298–307.
   PubMedGoogle Scholar
• Matheson J, Bourgault Z, Le Foll B. Sex differences in the neuropsychiatric effects and pharmacokinetics of cannabidiol: a scoping review. Biomolecules. 2022;12(10):1462.
   PubMed Web of Science ®Google Scholar
• Ergisi M, Erridge S, Harris M, et al. UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder. Expert Rev Clin Pharmacol. 2022;15(4):487–495.
   PubMed Web of Science ®Google Scholar
• Shannon S, Lewis N, Lee H, et al. Cannabidiol in anxiety and sleep: a large case series. Perm J. 2019;23(1):18–41.
   PubMedGoogle Scholar
• Martin EL, Strickland JC, Schlienz NJ, et al. Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial. Front Psychiatry. 2021;12:729800.
   PubMed Web of Science ®Google Scholar
• Drost L, DeAngelis C, Lam H, et al. Efficacy of different varieties of medical cannabis in relieving symptoms in post-traumatic stress disorder (PTSD) patients. J Pain Manage. 2017;10(4):415–422.
   Google Scholar
• Hser Y, Mooney LJ, Huang D, et al. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abuse Treat. 2017;81:53–58.
   PubMed Web of Science ®Google Scholar
• Baratta F, Simiele M, Pignata I, et al. Cannabis-based oral formulations for medical purposes: preparation, quality and stability. Pharmaceuticals. 2021;14(2):171.
   Web of Science ®Google Scholar
• Le QA, Doctor JN, Zoellner LA, et al. Minimal clinically important differences for the EQ-5D and QWB-SA in Post-traumatic Stress Disorder (PTSD): results from a Doubly Randomized Preference Trial (DRPT). Health Qual Life Outcomes. 2013;11(59):10.1186/1477-7525-11–59.
   PubMedGoogle Scholar
• Smith P, Slaven M, Shaw E, et al. Medical cannabis use in military and police veterans diagnosed with post-traumatic stress disorder (PTSD). J Pain Manage. 2017;10(4):397–405.
   Google Scholar
• Krediet E, Janssen DG, Heerdink ER, et al. Experiences with medical cannabis in the treatment of veterans with PTSD: results from a focus group discussion. Eur Neuropsychopharmacol. 2020;36:244–254.
   PubMed Web of Science ®Google Scholar
• Otis JD, Keane TM, Kerns RD. An examination of the relationship between chronic pain and post-traumatic stress disorder. J Rehabil Res Dev. 2003;40(5):397–405.
   PubMed Web of Science ®Google Scholar
• Asmundson GJG, Coons MJ, Taylor S, et al. PTSD and the experience of pain: research and clinical implications of shared vulnerability and mutual maintenance models. Can J Psychiatry. 2002;47(10):930–937.
   PubMed Web of Science ®Google Scholar
• Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neuroscience & Therapeutics. 2009;15(1):84–88. CNS neuroscience & therapeutics.
   PubMed Web of Science ®Google Scholar
• Jetly R, Heber A, Fraser G, et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:51 585–8.
   PubMed Web of Science ®Google Scholar
• Lancel M, van Marle HJF, Van Veen MM, et al. Disturbed sleep in PTSD: thinking beyond nightmares. Front Psychiatry. 2021;12:767760.
   PubMed Web of Science ®Google Scholar
• Mamelak M. Nightmares and the Cannabinoids. Curr Neuropharmacol. 2020;18(8):754–768.
   PubMed Web of Science ®Google Scholar
• Nicholson AN, Turner C, Stone BM, et al. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004;24(3):305–313.
   PubMed Web of Science ®Google Scholar
• Babson KA, Sottile J, Morabito DC. Cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep. 2017;19(4):23.
   PubMed Web of Science ®Google Scholar
• Loflin M, Earleywine M. No smoke, no fire: what the initial literature suggests regarding vapourized cannabis and respiratory risk. Can J Respir Ther. 2015;51(1):7–9.
   PubMedGoogle Scholar
• Loflin MJE, Earleywine M, Farmer S, et al. Placebo effects of edible cannabis: reported intoxication effects at a 30-minute delay. J Psychoactive Drugs. 2017;49(5):393–397.
   PubMed Web of Science ®Google Scholar
• Casarett D. The achilles heel of medical cannabis research-inadequate blinding of placebo-controlled trials. JAMA Intern Med. 2018;178(1):9–10.
   PubMed Web of Science ®Google Scholar
• Fear NT, Bridges S, Hatch S, et al. Posttraumatic stress disorder. In: NHS Digital, editor,Adult psychiatric morbidity survey 2014. England: Government Office; 2016. p. 106–130.
   Google Scholar
• Kluzek S, Dean B, Wartolowska KA. Patient-reported outcome measures (PROMs) as proof of treatment efficacy. BMJ Evid Based Med. 2022;27(3):153–155.
   PubMedGoogle Scholar